GeneExpression Systems, Inc. was incorporated in the Commonwealth of Massachusetts in 1999 by Harvard and MIT trained scientists. The company specializes in developing, applying, and marketing qualitative and quantitative differential gene profiling technology for downstream study of gene expression and regulation, diagnostic, predictive toxicology, and therapeutic purposes. GeneExpression Systems serves as a molecular biology contract research organization providing reagents and services to researchers in academic, biotechnology, and pharmaceutical industries within the emerging business segments of molecular cell biology, genomics, proteomics, and bioinformatics.
The company is focused on developing Differential Gene Profiling™ (DGP) tools to create a new functional genomics platform and maintain proprietary databases for medically relevant genes. Additionally, GeneExpression Systems collaborates with international companies to market compatible technology, instruments, and products in the US market. The company's mission is to lead in applying basic biology techniques and informatics tools in the fields of PharmacoGenomics, ToxicoGenomics, Proteomics, and Clinical Genomics to create proprietary high-value solutions in Applied Medical Sciences and beyond. Their commitment lies in discovering gene-markers for the early diagnosis of colon cancer, lung cancer, and inflammatory bowel diseases using state-of-the-art gene expression technology.
GeneExpression Systems, Inc. is at the forefront of biotechnology, information technology, and life sciences, with a core competency in the application of differential gene profiling (DGP) strategy for disease diagnosis.
